Fig. 1
Therapeutic effects of ADV on subcutaneous colorectal cancer model mice and its impact on the tumor microenvironment. (A) Schematic of the mouse treatment model. C57BL/6 and BALB/c mice were subcutaneously inoculated with 1 × 10⁶ MC38 or CT26 cells, respectively. When the tumors reached a volume of 50–100 mm³, intratumoral injections of 3 × 10⁸ PFU ADV were administered every other day for a total of three treatments. (B) Changes in subcutaneous tumor volume in the MC38 subcutaneous tumor model following treatment with PBS or ADVCtrl (n = 8 mice per group). (C) Survival curves of the mice in the different treatment groups (n = 8 mice per group). (D) Changes in mouse body weight during the treatment period (n = 8 mice per group). (E) Immune cell infiltration in the tumor microenvironment of MC38 subcutaneous tumors on days 7 and 14 after the first ADVCtrl treatment (n = 6 mice per group). (F) Changes in subcutaneous tumor volume in the CT26 subcutaneous tumor model following treatment with PBS or ADVCtrl (n = 8 mice per group). (G) Survival curves of the mice in different treatment groups (n = 8 mice per group). (H) Changes in mouse body weight during the treatment period (n = 8 mice per group). (I) Immune cell infiltration in the tumor microenvironment of CT26 subcutaneous tumors on days 7 and 14 after the first ADVCtrl treatment (n = 6 mice per group). The data are presented as the means ± standard deviations (SDs). NS, no significant difference; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001